{"id":750900,"date":"2023-04-25T10:51:33","date_gmt":"2023-04-25T14:51:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/"},"modified":"2023-04-25T10:51:33","modified_gmt":"2023-04-25T14:51:33","slug":"zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/","title":{"rendered":"ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <em>Parkinson\u2019s disease (\u201cPD\u201d), the second leading cause of neurodegeneration in the world, is characterized by progressive degeneration of nigrostriatal dopaminergic neurons and intracellular accumulation of aggregates containing misfolded fibrillar alpha<\/em><br \/>\n          <em>\u2011<\/em><br \/>\n          <em>synuclein (\u201c\u03b1<\/em><br \/>\n          <em>\u2011<\/em><br \/>\n          <em>synuclein&#8221;) in the remaining neurons<\/em>\n        <\/li>\n<li style=\"margin-bottom:8pt\">The authors observed a direct relationship between levels of ASC protein and misfolded \u03b1\u2011synuclein aggregates in PD mice brains, and concluded that ASC specks contribute to the propagation of inflammasome-associated \u03b1\u2011synuclein pathology in PD, which forms the basis for targeting ASC as a potential therapy for PD<\/li>\n<\/ul>\n<p>WESTON, Fla., April  25, 2023  (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed <em>Journal of Neuroinflammation <\/em>supporting the potential of ASC specks as a therapeutic target for Parkinson\u2019s disease.<\/p>\n<p>In the paper titled, \u201cASC specks exacerbate \u03b1\u2011synuclein pathology via amplifying NLRP3 inflammasome activities,\u201d the authors reported data on the interplay between ASC speck formation, NLRP3 inflammasome activation, and pathological progression in a PD model (induced by human A53T mutant \u03b1-synuclein preformed fibrils, \u201cPFFs\u201d). Following is a summary of key findings:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">There was a direct relationship between \u03b1\u2011synuclein pathology and ASC expression<\/li>\n<li style=\"margin-bottom:8pt\">ASC specks enhanced NLRP3 inflammasome activation and reactive microgliosis<\/li>\n<li style=\"margin-bottom:8pt\">ASC specks accelerated dopaminergic neuron degeneration and dyskinesia (uncontrolled, involuntary movement)<\/li>\n<li style=\"margin-bottom:8pt\">Knockdown of endogenous ASC markedly suppressed microglial inflammasome activation and neuronal \u03b1\u2011synuclein aggregation under the challenge of PFFs<\/li>\n<\/ul>\n<p>The authors stated, \u201cThere is a clear association between ASC specks assembly, NLRP3 inflammasome activation, and PD pathological progression, especially with regards to \u03b1\u2011synuclein accumulation. These findings imply that targeting ASC is a promising therapeutic approach for PD.\u201d\u00a0\u00a0 To read the article <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y9Z2RcxOca97IGrrx8eu1AEQct9mIMB9mi90ZmJv-DL6d8gAFLB-kjK8dFJTXJcDfdp4OsCWlcsrC1l5c4QsMKbk9ifkwgaDIdg41ps9-BkHQx15LMg_LgjqJNm913v6\" rel=\"nofollow noopener\" target=\"_blank\">Click Here<\/a>.<\/p>\n<p>Stephen C. Glover, ZyVersa\u2019s Co-founder, Chairman, CEO and President, stated: \u201cThe research on the role of ASC Specks in propagation of alpha-synuclein pathology in Parkinson\u2019s disease published in the <em>Journal of Neuroinflammation<\/em> provides additional support for the therapeutic potential of ZyVersa\u2019s proprietary monoclonal antibody Inflammasome ASC Inhibitor IC 100, in neurological diseases. IC 100 preclinical studies demonstrate reduced inflammatory activity and\/or improved outcomes in, age-related inflammation, Alzheimer\u2019s disease, multiple sclerosis, spinal cord injury, and two different models of brain injury.\u201d<\/p>\n<p>\n        <strong>About Inflammasome ASC Inhibitor IC 100<\/strong>\n      <\/p>\n<p>IC 100 is a novel humanized IgG4 monoclonal antibody that inhibits the inflammasome adaptor protein ASC. IC 100 was designed to attenuate both initiation and perpetuation of the inflammatory response. It does so by binding to a specific region of the ASC component of multiple types of inflammasomes, including NLRP1, NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to ASC monomers, inhibiting inflammasome formation, thereby blocking activation of IL-1\u03b2 early in the inflammatory cascade. IC 100 also binds to ASC in ASC Specks, both intracellularly and extracellularly, further blocking activation of IL-1\u03b2 and the perpetuation of the inflammatory response that is pathogenic in inflammatory diseases. Because active cytokines amplify adaptive immunity through various mechanisms, IC 100, by attenuating cytokine activation, also attenuates the adaptive immune response.<\/p>\n<p>\n        <strong>About ZyVersa Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies \u2013 Cholesterol Efflux Mediator\u2122 VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and other inflammatory diseases. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4E04YYRRu-Fs9RKRp0GHqD1QHGKxh3TY2jaT4A3ore11iv-6DgcpViEvmaGU67rO_daA0-gJH8jyi2tKAPyfyQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.zyversa.com<\/a>.<\/p>\n<p>\n        <strong>Cautionary Statement Regarding Forward-Looking Statements <\/strong>\n      <\/p>\n<p>Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management\u2019s intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc (\u201cZyVersa\u201d) uses words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cprojects,\u201d \u201cfuture,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cguidance,\u201d and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa\u2019s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa\u2019s plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa\u2019s planned preclinical and clinical trials; the timing of the availability of data from ZyVersa\u2019s preclinical and clinical trials; the timing of any planned investigational new drug application or new drug application; ZyVersa\u2019s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa\u2019s product candidates; ZyVersa\u2019s commercialization, marketing and manufacturing capabilities and strategy; ZyVersa\u2019s ability to protect its intellectual property position; and ZyVersa\u2019s estimates regarding future revenue, expenses, capital requirements and need for additional financing.<\/p>\n<p>New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.<\/p>\n<p>This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities.<\/p>\n<p>\n        <strong>Corporate and IR Contact:<\/strong><br \/>\n        <br \/>Karen Cashmere<br \/>Chief Commercial Officer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_F30MHLK9rvftx4yJk31QxJXcUIFnfj_CopOUdwi_Dk8SuzPH2Ea0rNDeRZGz0-GZGwOrpWDUAEClu1xIKxBRr6S6qM8-qdYClUOqSzhEp0=\" rel=\"nofollow noopener\" target=\"_blank\">kcashmere@zyversa.com<\/a><br \/>786-251-9641\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong>Media Contacts<\/strong><br \/>\n        <br \/>\n        <strong>Tiberend Strategic Advisors, Inc.<\/strong><br \/>\n        <br \/>Casey McDonald<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=proS7xaUpbnqp644sHGqpN1qx-e2XxvpUNz6NKlLmPQBpfJtXF2nqn7Z01a_igByHBX8ZwOuJFmnJ-qndT1A71CG9kMTWXcn9XF-g5ozt2E=\" rel=\"nofollow noopener\" target=\"_blank\">cmcdonald@tiberend.com<\/a><br \/>646-577-8520<\/p>\n<p>Dave Schemelia<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s29XX7HlFUMOymjDqPWn5uSiWZNQFh-UN0HwipP3PBok38dWsqSQq23_DnnuWxXUMETvfSCLVgtqpfVLxJcd-FFfGQTOKcO2iivEQIO2QS8=\" rel=\"nofollow noopener\" target=\"_blank\">dschemelia@tiberend.com<\/a><br \/>609-468-9325<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzg5OCM1NTUyNzYzIzIyNDQ1MTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmVmYTEyZmItODhkOC00YTRiLWEzNWMtNjNhOTYwOTM2ZWY3LTEyNTYwNjk=\/tiny\/ZyVersa-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Parkinson\u2019s disease (\u201cPD\u201d), the second leading cause of neurodegeneration in the world, is characterized by progressive degeneration of nigrostriatal dopaminergic neurons and intracellular accumulation of aggregates containing misfolded fibrillar alpha \u2011 synuclein (\u201c\u03b1 \u2011 synuclein&#8221;) in the remaining neurons The authors observed a direct relationship between levels of ASC protein and misfolded \u03b1\u2011synuclein aggregates in PD mice brains, and concluded that ASC specks contribute to the propagation of inflammasome-associated \u03b1\u2011synuclein pathology in PD, which forms the basis for targeting ASC as a potential therapy for PD WESTON, Fla., April 25, 2023 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-750900","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Parkinson\u2019s disease (\u201cPD\u201d), the second leading cause of neurodegeneration in the world, is characterized by progressive degeneration of nigrostriatal dopaminergic neurons and intracellular accumulation of aggregates containing misfolded fibrillar alpha \u2011 synuclein (\u201c\u03b1 \u2011 synuclein&#8221;) in the remaining neurons The authors observed a direct relationship between levels of ASC protein and misfolded \u03b1\u2011synuclein aggregates in PD mice brains, and concluded that ASC specks contribute to the propagation of inflammasome-associated \u03b1\u2011synuclein pathology in PD, which forms the basis for targeting ASC as a potential therapy for PD WESTON, Fla., April 25, 2023 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of &hellip; Continue reading &quot;ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T14:51:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzg5OCM1NTUyNzYzIzIyNDQ1MTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease\",\"datePublished\":\"2023-04-25T14:51:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/\"},\"wordCount\":1035,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzg5OCM1NTUyNzYzIzIyNDQ1MTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/\",\"name\":\"ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzg5OCM1NTUyNzYzIzIyNDQ1MTY=\",\"datePublished\":\"2023-04-25T14:51:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzg5OCM1NTUyNzYzIzIyNDQ1MTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyMzg5OCM1NTUyNzYzIzIyNDQ1MTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/","og_locale":"en_US","og_type":"article","og_title":"ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease - Market Newsdesk","og_description":"Parkinson\u2019s disease (\u201cPD\u201d), the second leading cause of neurodegeneration in the world, is characterized by progressive degeneration of nigrostriatal dopaminergic neurons and intracellular accumulation of aggregates containing misfolded fibrillar alpha \u2011 synuclein (\u201c\u03b1 \u2011 synuclein&#8221;) in the remaining neurons The authors observed a direct relationship between levels of ASC protein and misfolded \u03b1\u2011synuclein aggregates in PD mice brains, and concluded that ASC specks contribute to the propagation of inflammasome-associated \u03b1\u2011synuclein pathology in PD, which forms the basis for targeting ASC as a potential therapy for PD WESTON, Fla., April 25, 2023 (GLOBE NEWSWIRE) &#8212; ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or \u201cZyVersa\u201d), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of &hellip; Continue reading \"ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-25T14:51:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzg5OCM1NTUyNzYzIzIyNDQ1MTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease","datePublished":"2023-04-25T14:51:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/"},"wordCount":1035,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzg5OCM1NTUyNzYzIzIyNDQ1MTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/","name":"ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzg5OCM1NTUyNzYzIzIyNDQ1MTY=","datePublished":"2023-04-25T14:51:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzg5OCM1NTUyNzYzIzIyNDQ1MTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyMzg5OCM1NTUyNzYzIzIyNDQ1MTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/zyversa-therapeutics-announces-publication-of-an-article-in-the-journal-of-neuroinflammation-addressing-the-role-of-asc-specks-in-propagation-of-alpha-synuclein-pathology-in-parkinsons-diseas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson\u2019s Disease"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=750900"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750900\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=750900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=750900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=750900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}